Conversely, in an animal model study, empagliflozin reduced the ratios of p-Smad2/Smad2 and p-Smad3/Smad3, enhanced the effect of Smad7, and downregulated the production of TGF-β1 in DM mice [56]. Here, SMAD3 is linked to diabetes mellitus.